Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms
Open Access
- 30 August 2012
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 5 (9) , 890-898
Abstract
In this review, we focus on how inhibitors of Hsp90 can help prevent the resistance to anti-cancer drugs by synergistically increasing their cancer killing abilities and thereby allowing them to function at much lower concentrations than normally used. Hsp90 helps to fold numerous client proteins, such as Akt, Raf, Src, chromatin-modifying proteins, nuclear hormone receptors, and kinetochore assembly proteins. We discuss four mechanisms by which Hsp90 inhibitors can potentially synergize with anti-cancer drugs: by making a drug-resistant protein that is a client for Hsp90 more sensitive to the drug, by increasing chromosomal aneuploidy and the effectiveness of DNA-damaging drugs, by inhibiting Trithorax proteins which trimethylate histone 3 at lysine 4 (H3K4me3) and thereby decreasing expression of tumor promoter genes, and by interacting with the negative elongation factor (NELF) complex in tumors. We also explain how the evolutionary capacitor function of Hsp90 can be exploited with inhibitors of Hsp90 by exposing new protein variants that can be targeted with other drugs, thereby opening new avenues of combination drug therapy to treat cancer. We believe that inhibition of these processes can increase the efficacy of Hsp90 inhibitors with other anti-cancer drugs.Keywords
This publication has 32 references indexed in Scilit:
- Hsp90 Globally Targets Paused RNA Polymerase to Regulate Gene Expression in Response to Environmental StimuliCell, 2012
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse MechanismsClinical Cancer Research, 2012
- Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsBiochemical Pharmacology, 2012
- Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidyNature, 2012
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionJournal of Experimental Medicine, 2012
- Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongationBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2011
- Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expressionProceedings of the National Academy of Sciences, 2009
- Cisplatin abrogates the geldanamycin-induced heat shock responseMolecular Cancer Therapeutics, 2008
- The EDGE hypothesis: Epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancerFrontiers in Neuroendocrinology, 2008
- Hsp90 as a capacitor of phenotypic variationNature, 2002